KRRO
Korro Bio, Inc.
Next earnings Aug 10, 2026 · consensus $-1.41 EPS, $219K rev
Last earnings -3.4% on 2026-05-07
$12.70
▲ +4.36%$12.70▲ +8.09%
over 1Y
L $5.28EODHDH $51.36
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.4%
1W-8.6%
1M-7.7%
3M+22.1%
YTD+57.8%
1Y+8.1%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Buy
Revenue grew 181.5% YoY; but unprofitable (net margin -1834.5%).
Revenue (FY2025) $6.39M · FY2025
Korro Bio, Inc. shows $6.39M in FY2025 revenue (+181.5% YoY), a -1834.5% net margin, and -228.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $2.27M | $6.39M |
| Gross profit | — | — | — | — | — |
| Operating income | -$84.0M | -$59.0M | -$84.5M | -$91.9M | -$122M |
| Net income | -$84.7M | -$58.0M | -$81.2M | -$83.6M | -$117M |
| Diluted EPS | — | -$227.42 | -$53.08 | -$9.37 | -$12.48 |
| Net margin | — | — | — | -3680.4% | -1834.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$172M
EV / EBITDA—
EV / Sales26.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-64.0%
FCF yield-43.2%
Quality & risk
ROIC (est.)-156.2%
Free cash flow-$79.1M
Total debt$10.2M
Net cash$11.6M
Altman Z-Score-5.71 distress
Piotroski F-Score2/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+53.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-222026-06-24open ↗144Filing2026-06-24open ↗144Filing2026-06-24open ↗144Filing2026-06-23open ↗144Filing2026-06-23open ↗144Filing2026-06-22open ↗144Filing2026-06-22open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗144Filing2026-06-16open ↗
Frequently asked
- Is Korro Bio, Inc. (KRRO) a buy?
- KRRO currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 181.5% YoY; but unprofitable (net margin -1834.5%).
- What is Korro Bio, Inc.'s quality score?
- KRRO scores 38.09803921568627/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001703647, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 7:15:07 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.